Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326961 · ClinicalTrials.gov registry record · Phase 2
Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee
A Phase 2 study of Osteoarthritis, Knee, sponsored by Cytori Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 11
- Study locations
NCT02326961: Completed Phase 2 study of Osteoarthritis, Knee, sponsored by Cytori Therapeutics.
NCT02326961 is a Phase 2 study of Osteoarthritis, Knee that has completed, run by Cytori Therapeutics. The registered enrollment target is 94 participants, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (81% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326961, a Phase 2 study of Osteoarthritis, Knee, has completed, sponsored by Cytori Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 11
- Study locations
Study Summary
The primary objective of this study is to evaluate the safety and feasibility of intraarticular injection of Celution prepared adipose-derived regenerative cells injected into knees of patients with chronic knee pain due to osteoarthritis.
Conditions Studied
Interventions
- OTHER Placebo
- DEVICE Celution Device
Study Locations (11)
Arizona
- Arizona Arthritis and Rheumatology Research, PLLC - Mesa
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
California
- BioSolutions Clinical Research Center - La Mesa
Illinois
- Rush University Medical Center - Chicago
Kansas
- Heartland Research Associates - Wichita
Kentucky
- Central Kentucky Research Associates - Lexington
Louisiana
- Covington Orthopedic and Sports Medicine Institute - Covington
Maryland
- Arthritis Treatment Center - Frederick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
What the finished NCT02326961 record still lists
NCT02326961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02326961 lists 11 locations in 11 states (Arizona, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT02326961 about?
NCT02326961 is a clinical study titled "Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee". The primary objective of this study is to evaluate the safety and feasibility of intraarticular injection of Celution prepared adipose-derived regenerative cells injected into knees of patients with chronic knee pain due to osteoarthritis.
What is the current status of trial NCT02326961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2015-01. Estimated completion is 2016-10.
What conditions does trial NCT02326961 study?
This clinical trial studies the following conditions: Osteoarthritis, Knee.
What interventions are being tested in trial NCT02326961?
The interventions under investigation include: Placebo (OTHER), Celution Device (DEVICE).
Who is sponsoring clinical trial NCT02326961?
This trial is sponsored by Cytori Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02326961 being conducted?
This trial has 11 study locations across Arizona, Arkansas, California, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02326961's enrollment target sits among peer trials
94 70th of 112 higher than 43 of 112 other Osteoarthritis, Knee trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preventing Injured Knees From osteoArthritis: Severity Outcomes
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty
RECRUITING · Phase 2
-
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
RECRUITING · Phase 2
-
A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia